ELI LILLY AND COMPANY Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense
ELI LILLY AND COMPANY (LLY) reported Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense of $20.50 million for the 12-month period ending 2021-12-31, per its 10-K filed 2022-02-23.
Discontinued › Expense Statement › Interest Expense
us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense · last filed 2022-02-23
- ELI LILLY AND COMPANY unrecognized tax benefits, income tax penalties and interest expense for fiscal 2021 was $20.50M, a 39.71% decline from fiscal 2020.
- ELI LILLY AND COMPANY unrecognized tax benefits, income tax penalties and interest expense for fiscal 2020 was $34.00M.
- ELI LILLY AND COMPANY unrecognized tax benefits, income tax penalties and interest expense for fiscal 2019 was -$26.40M, a 205.18% decline from fiscal 2018.
- ELI LILLY AND COMPANY unrecognized tax benefits, income tax penalties and interest expense for fiscal 2018 was $25.10M, a 10.09% increase from fiscal 2017.
| Period end | Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense 12 month | Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense 12 month as first filed |
|---|---|---|
| 2021-12-31 | $20.50M 10-K · filed 2022-02-23 | |
| 2020-12-31 | $34.00M 10-K · filed 2022-02-23 | |
| 2019-12-31 | -$26.40M 10-K · filed 2022-02-23 | |
| 2018-12-31 | $25.10M 10-K · filed 2021-02-17 | $24.40M 10-K · filed 2019-02-19 |
| 2017-12-31 | $22.80M 10-K · filed 2020-02-19 | $27.40M 10-K · filed 2018-02-20 |
| 2016-12-31 | -$63.80M 8-K · filed 2019-10-24 | -$52.50M 10-K · filed 2017-02-21 |
| 2015-12-31 | $13.20M 10-K · filed 2018-02-20 | |
| 2014-12-31 | $35.90M 10-K · filed 2017-02-21 | |
| 2013-12-31 | -$10.90M 10-K · filed 2016-02-19 | $10.90M 10-K · filed 2014-02-19 |
| 2012-12-31 | $42.30M 10-K · filed 2015-02-19 | |
| 2011-12-31 | $47.30M 10-K · filed 2014-02-19 | -$47.30M 10-K · filed 2012-02-24 |
| 2010-12-31 | $38.30M 10-K · filed 2013-02-21 | |
| 2009-12-31 | -$1.90M 10-K · filed 2012-02-24 | |
| 2008-12-31 | -$118.00M 10-K · filed 2011-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Akari Therapeutics Plc (AKTX) | $1,527.991B | -47,921.42 | |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |